KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery.

Lee, Jeong Won; Lee, Jong Hoon; Shim, Byoung Yong; Kim, Sung Hwan; Chung, Mi-Joo; Kye, Bong-Hyeon; Kim, Hyung Jin; Cho, Hyeon Min; Jang, Hong Seok

Lee, Jeong Won; Lee, Jong Hoon; Shim, Byoung Yong; Kim, Sung Hwan; Chung, Mi-Joo; Kye, Bong-Hyeon; Kim, Hyung Jin; Cho, Hyeon Min; Jang, Hong Seok.

Affiliation

Lee JW; From the Department of Radiation Oncology, Seoul St. Mary's Hospital (JWL, HSJ); Department of Radiation Oncology (JHL, SHK, MJC); Department of Medical Oncology (BYS); Department of Colorectal Surgery, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea (B-HK, HJK, HMC).

Medicine (Baltimore) ; 94(31): e1284, 2015 Aug.

Article in En | MEDLINE | ID: mdl-26252300

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rectal Neoplasms / Adenocarcinoma / Proto-Oncogene Proteins / Ras Proteins / Mutation Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Medicine (Baltimore) Year: 2015 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google